Reata Pharmaceuticals - RETA Stock Forecast, Price & News

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Reata Pharmaceuticals in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RETA shares.
View RETA analyst ratings or view top-rated stocks.

6 Wall Street research analysts have issued 1-year price objectives for Reata Pharmaceuticals' stock. Their RETA share price forecasts range from $67.00 to $138.00. On average, they anticipate the company's stock price to reach $96.89 in the next year. This suggests a possible upside of 9.4% from the stock's current price.
View analysts price targets for RETA or view top-rated stocks among Wall Street analysts.

Reata Pharmaceuticals' stock was trading at $37.99 at the beginning of the year. Since then, RETA shares have increased by 133.0% and is now trading at $88.53.
View the best growth stocks for 2023 here.

Reata Pharmaceuticals saw a decrease in short interest in March. As of March 15th, there was short interest totaling 5,030,000 shares, a decrease of 39.8% from the February 28th total of 8,360,000 shares. Based on an average daily volume of 1,420,000 shares, the days-to-cover ratio is currently 3.5 days. Approximately 18.1% of the company's shares are short sold.
View Reata Pharmaceuticals' Short Interest.

Reata Pharmaceuticals, Inc. (NASDAQ:RETA) announced its quarterly earnings data on Monday, November, 8th. The company reported ($1.97) EPS for the quarter, topping analysts' consensus estimates of ($2.32) by $0.35. The business earned $7.40 million during the quarter, compared to analyst estimates of $2.07 million. Reata Pharmaceuticals had a negative trailing twelve-month return on equity of 922.50% and a negative net margin of 9,897.91%. The company's revenue was up 428.6% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.94) EPS.

ETFs with the largest weight of Reata Pharmaceuticals (NASDAQ:RETA) stock in their portfolio include Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Invesco DWA Healthcare Momentum ETF (PTH), SPDR S&P Pharmaceuticals ETF (XPH), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Invesco Nasdaq Future Gen 200 ETF (QQQS), iShares U.S. Pharmaceuticals ETF (IHE), Principal Healthcare Innovators ETF (BTEC) and Invesco Nasdaq Biotechnology ETF (IBBQ).

10 employees have rated Reata Pharmaceuticals Chief Executive Officer Warren Huff on Glassdoor.com. Warren Huff has an approval rating of 92% among the company's employees. This puts Warren Huff in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Reata Pharmaceuticals investors own include Approach Resources (AREX), Precision Drilling (PDS), First Financial Bankshares (FFIN), Synlogic (SYBX), NVIDIA (NVDA), Basic Energy Services (BAS), Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO) and Archrock (AROC).

(RETA) raised $60 million in an initial public offering on Thursday, May 26th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Cowen and Company and Piper Jaffray served as the underwriters for the IPO.

Reata Pharmaceuticals trades on the NASDAQ under the ticker symbol "RETA."

Reata Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include First Light Asset Management LLC (5.63%), Fred Alger Management LLC (4.12%), Deutsche Bank AG (4.07%), Boxer Capital LLC (3.36%), Morgan Stanley (2.00%) and Emerald Advisers LLC (1.86%). Insiders that own company stock include Andrea Loewen, Bhaskar Anand, Colin John Meyer, Dawn Carter Bir, Elaine Castellanos, James Warren Huff, Manmeet Singh Soni, Michael D Wortley, Samina Khan and Shamim Ruff.
View institutional ownership trends.

Shares of RETA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RETA stock can currently be purchased for approximately $88.53.

Reata Pharmaceuticals (NASDAQ:RETA) has a market capitalization of $3.25 billion and generates $2.22 million in revenue each year. The company earns $-311,900,000.00 in net income (profit) each year or ($8.56) on an earnings per share basis.

The company employs 346 workers across the globe.

Reata Pharmaceuticals' mailing address is 5320 LEGACY DRIVE, PLANO TX, 75024. The official website for the company is www.reatapharma.com. The company can be reached via phone at (972) 865-2219 or via email at ir@reatapharma.com.